What cancer is associated with low Complement 3 (C3) and CD8 (8c) cell subsets in leukocytes in a patient with an autoimmune disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Patients with autoimmune diseases who have abnormalities in C3 complement and B-cell leukocytes, such as those with chronic lymphocytic leukemia (CLL), are at an increased risk for developing autoimmune cytopenias, which may precede or complicate CLL, and potentially other lymphoproliferative disorders. The association between autoimmune diseases and lymphoma risk is well-documented, with conditions like CLL showing a link to autoimmune hemolytic anemia (AIHA) and autoimmune thrombocytopenia (ITP) 1. The pathophysiology involves immune dysregulation, where nonmalignant B lymphocytes produce polyclonal high-affinity immunoglobulin G (IgG) via a T-cell-mediated mechanism, leading to antibody-dependent cellular cytotoxicity 1.

Key points to consider in the management of these patients include:

  • The concept that autoimmune cytopenia may precede CLL, highlighting the need for early detection and monitoring 1
  • The importance of distinguishing between "simple autoimmunity" and "complex autoimmunity" in the context of CLL, as this may impact prognosis and treatment approach 1
  • The role of CLL cells as antigen-presenting cells, inducing the formation of autoreactive T-helper cells and nonfunctional T-regulatory cells, contributing to the development of autoimmunity 1
  • The need for regular monitoring with complete blood counts and prompt evaluation of unexplained symptoms to enable early detection of potential malignancies

In terms of specific cancer association, CLL is a notable concern in patients with autoimmune diseases and abnormalities in C3 complement and B-cell leukocytes, given its link to autoimmune cytopenias and potential for malignant transformation 1. Therefore, it is essential to prioritize regular monitoring and early detection strategies in these patients to mitigate the risk of lymphoproliferative disorders.

From the Research

Autoimmune Disease and Associated Cancers

  • Autoimmune disorders are associated with an increased risk of developing certain types of cancer, particularly lymphomas 2.
  • The exact mechanisms of this association are not fully understood, but it is thought to involve the interplay of various immune cells, including T cells and B cells, as well as the production of autoantibodies 3, 4.

Leukocyte Subtypes and Associated Cancers

  • C3 and 8c cells are subsets of leukocytes that have been implicated in the development of autoimmune diseases and associated cancers 4.
  • T cells, including CD4+ and CD8+ T cells, play a central role in the regulation of the immune system and can contribute to the development of autoimmune diseases and associated cancers 4.
  • Plasma cells, which are responsible for the production of autoantibodies, have also been implicated in the development of autoimmune diseases and associated cancers 5.

Specific Cancers Associated with Autoimmune Diseases

  • Lymphomas, including non-Hodgkin lymphoma and Hodgkin lymphoma, are commonly associated with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis 2.
  • Other types of cancer, including multiple myeloma and Waldenström's macroglobulinemia, have also been associated with autoimmune diseases 5.
  • The complement system, which is involved in the regulation of the immune system, has also been implicated in the development of autoimmune diseases and associated cancers 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

T Lymphocytes and Autoimmunity.

International review of cell and molecular biology, 2018

Research

Complement Therapeutics in Autoimmune Disease.

Frontiers in immunology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.